The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies von Baldwin, David S, Chrones, Lambros, Florea, Ioana, Nielsen, Rebecca, Nomikos, George G, Palo, William, Reines, Elin

Volltext

Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness von Baldwin, David S., Necking, Oscar, Schmidt, Simon Nitschky, Ren, Hongye, Reines, Elin H.

Volltext

Management of Depression in Adolescents in Japan von Saito, Takuya, Reines, Elin H, Florea, Ioana, Dalsgaard, Mads K

Volltext

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study von Wang, Gang, Xiao, Le, Ren, Hongye, Simonsen, Kenneth, Ma, Jingdong, Xu, Xiangdong, Guo, Ping, Wang, Zhiren, Bai, Ludong, Reines, Elin Heldbo, Hammer-Helmich, Lene

Volltext

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo von Baldwin, David S, Asakura, Satoshi, Koyama, Tsukasa, Hayano, Taiji, Hagino, Atsushi, Reines, Elin, Larsen, Klaus

Volltext

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea von Moon, Seok Woo, Kim, Jee Wook, Kim, Do Hoon, Lee, Kyu Young, Reines, Elin Heldbo, Lee, Minah, Park, Yoo Jin

Volltext

Management of Depression in Adolescents in Japan von Saito, Takuya, Reines, Elin H., Florea, Ioana, Dalsgaard, Mads K.

Volltext

Escitalopram in the long-term treatment of major depressive disorder von Wade, Alan, Despiegel, Nicolas, Heldbo Reines, Elin

Volltext

Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder von McIntyre, Roger S., Necking, Oscar, Schmidt, Simon Nitschky, Reines, Elin

Volltext

Escitalopram Therapy for Major Depression and Anxiety Disorders von Baldwin, David S, Reines, Elin Heldbo, Guiton, Christina, Weiller, Emmanuelle

Volltext

Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea von Moon, Seok Woo, Kim, Jee Wook, Kim, Do Hoon, Adair, Michael, Åström, Daniel, Reines, Elin, Lee, Minah, Kim, Gayoung

Volltext

Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies von Chick, Jonathan, Andersohn, Frank, Guillo, Sylvie, Borchert, Kathrin, Toussi, Massoud, Braun, Sebastian, Haas, Jennifer S, Kuppan, Kavitha, Lemming, Ole M, Reines, Elin Heldbo, Tubach, Florence

Volltext

Escitalopram versus citalopram: the surprising role of the R-enantiomer von SANCHEZ, Connie, BØGESØ, Klaus P, EBERT, Bjarke, REINES, Elin Heldbo, BRAESTRUP, Claus

Volltext

Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-l... von Mahableshwarkar, Atul R., Affinito, John, Reines, Elin Heldbo, Xu, Judith, Nomikos, George, Jacobsen, Paula L.

Volltext

Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care von Lepola, Ulla M, Loft, Henrik, Reines, Elin Heldbo

Volltext

The cardiovascular safety profile of escitalopram von Thase, Michael E, Larsen, Klaus G, Reines, Elin, Kennedy, Sidney H

Volltext

A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder von Colonna, Lucien, Andersen, Henning Friis, Reines, Elin Heldbo

Volltext

Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post... von Demyttenaere, Koen, Reines, Elin Heldbo, Lönn, Sara Larsson, Lader, Malcolm

Volltext

Escitalopram in the Long-term Treatment of Major Depressive Disorder von Wade, Alan, Despiegel, Nicolas, Heldbo Reines, Elin

Volltext

Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care von Lepola, Ulla M., Loft, Henrik, Reines, Elin Heldbo

Volltext